GlassScriptPhysician profile
Sandy Milgraum
NPI 1568498376
$1,062.47
in general payments reported to CMS, 2019-2025
15 companies · $156 in 2025
The $156 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $68.54 · 2021: $99.03 · 2022: $220 · 2023: $312 · 2024: $96.01 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $469.99 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $442.44 | 2022-2024 | Tremfya, Remicade, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $186.81 | 2019-2024 | Arazlo, Cabtreo |
| Galderma Laboratories, L.P. | $139.35 | 2025 | Nemluvio |
| Leo Pharma INC. | $66.06 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $41.38 | 2022-2024 | Nuzyra |
| Abbvie INC. | $29.73 | 2021-2025 | |
| Dermavant Sciences, INC. | $29.23 | 2023 | Vtama |
| Pfizer INC. | $24.27 | 2022 | |
| Sun Pharmaceutical Industries INC. | $15.22 | 2022 | |
| Arcutis Biotherapeutics, INC. | $14.96 | 2023 | |
| Genzyme Corporation | $14.93 | 2021 | |
| Epi Health, LLC | $14.87 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.67 | 2024 | Acthar |
| Nabriva Therapeutics, Plc | $14.34 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $14.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Milgraum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.